Check out the final results of our IST of sotatercept for anemia of MF published in Haematologica: 55 patients, RR around 30% both alone and with rux MD Anderson Cancer Center Bristol Myers Squibb Hagop Kantarjian,MD #sergeverstovsek #MPNSM
doi.org/10.3324/haemat…

Registration is open for the 16th Int'l MPN Congress!
🗓️Oct 24-25 🏙️Brooklyn, NY ➡️Details at bit.ly/MPNcongress2024
#MPNCongress2024 #MPNsm #MyeloproliferativeNeoplasms #myelofibrosis

Single Cell Genomics Day starts tomorrow at 10AM ET!

Come for the awesome keynotes (Jason Buenrostro , Xiaowei Zhuang, IdoAmitLab) and to learn about our favorite new methods and trends for the field in the last year. All talks streamed on Youtube and satijalab.org/scgd

Our review is published online ⁦Blood Advances⁩ : patients w PV <60y of age, cytoRx esp w IFN is not so bad! So why isn’t it standard of care yet? Congratulations ⁦Reem Chamseddine,⁩ ⁦WeillCornellQatar⁩ students, ⁦Weill Cornell Medicine⁩ coauthors ashpublications.org/bloodadvances/…

📣 #ESHMPN2024 STARTS IN ONLY 6 WEEKS!
Let's meet on April 26th in Mandelieu-La Napoule 🇫🇷
REGISTER NOW ➡️ bit.ly/3PALAGS
10th Translational Research Conference
MYELOPROLIFERATIVE NEOPLASMS
Chairs: J.J. Kiladjian, Ross Levine, Jyoti Nangalia
#ESHCONFERENCES #MPNsm

Last week, Miami Cancer Institute Research hosted the fifth annual Global Summit on Immunotherapies for Hematologic Malignancies which brought together the world's leading experts in treating #leukemia , #lymphoma , and multiple #myeloma through novel immunotherapies and treatment combinations.…

Wonderful to have our paper 'Deciphering cell states and genealogies of human haematopoiesis' led by Chen Weng, in a great collaboration with Jonathan Weissman's Lab, published today in nature:
nature.com/articles/s4158…

The ISEH community deeply mourns the loss of Connie Eaves; a revered society member, Past President, former ExpHem journal editor, and incredible scientist. Connie will be remembered not only for her seminal works, but for her generous mentorship of generations of scientists.

Welcome to the 2024 Global Summit on Immunotherapies for Hematologic Malignancies!

Dr. Guenther Koehne gives opening remarks introducing the full line up of speakers and the emerging updates in treatment options 💡

#HemOnc #leukemia #OncTwitter

#MCIImmunotherapySummit

💡 A full house and great insights from Dr. Guenther Koehne with the latest advancements in #CART cell therapy for #AML 🩸

#MCIImmunotherapySummit
#MedEd #HemOnc #leusm

Thank you🗣️ Dr. Saad Usmani (Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Memorial Sloan Kettering Cancer Center) discussing the implications and important considerations for #stemcell transplant for multiple #myeloma

#SCT #multiplemyeloma #MedTwitter
#MCIImmunotherapySummit

Happy to be at Miami Cancer Institute immunotherapy in Heme malignancies meeting. Terrific meeting . We now have much to discuss when talking about immunotherapy in MPNs (and much to prove) Miami Cancer Institute Research #mpnsm Memorial Sloan Kettering Cancer Center

Registration is open for the 16th Int'l MPN Congress, to be held on Oct 24-25 in Brooklyn, New York! Details at bit.ly/MPNcongress2024
#MPNCongress2024 #MPNsm #MyeloproliferativeNeoplasms #myelofibrosis #CME #CE #hemonc

#mpnsm - How do you assess response to blast reduction therapy in AP/BP MPN; Princess Margaret Experience - Outcomes of intensive and non-intensive blast-reduction strategies in AP/BP MPN sciencedirect.com/science/articl…

In case you missed it, Check out our website for access to the 2024 Indy Hematology Review Presentation! indyhematologyreview.com/2024-presentat…
#IHR24 #IndyHematology

Indy Hematology meeting. First time attending. Terrific meeting on all aspects of hematology. Honored to join the illustrious group of speakers at this meeting.

Excited to see this published in NEJM. Phase 2 results of REVIVE - studying the efficacy of the hepcidin mimetic, rusfertide in phlebotomy dependent patients with PV. #MPNSM . Phase 3 VERIFY study is ongoing. Naveen Pemmaraju, MD Aaron Gerds MD, MS Jeanne M Palmer Abdulraheem Yacoub Moffitt Cancer Center

'Ivosidenib significantly reduced posaconazole and voriconazole levels. Vori should be avoided, empiric high-dose posa (>300 mg/day) may be considered, and therapeutic drug monitoring is recommended in all patients receiving concomitant ivosidenib.' Benyam Muluneh, PharmD, BCOP Katie Buhlinger

Raajit Rampal, M.D.Ph.D. gave an overview of the classification, risk assessment, and current therapy options for patients with #myelofibrosis . #MPNSM | Memorial Sloan Kettering Cancer Center

targetedonc.com/view/jak-stat-…

Moving toward disease modification in polycythemia vera | bLoOd | Dr Jan Bewersdorf & ⁦Raajit Rampal, M.D.Ph.D.⁩ | ⁦Joan How⁩ Naveen Pemmaraju, MD⁩ Mascarenhas ⁦Lucia Masarova, MD⁩ ⁦Prithviraj Bose⁩ || #MPNSM | ⁦Heme Reports⁩ ashpublications.org/blood/article/…